AKBA - FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia | Benzinga
Wednesday, the FDA approved Akebia Therapeutics Inc (NASDAQ:AKBA) Vafseo (vadadustat) tablets for anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months.
Vafseo is a once-daily oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that activates the physiologic response to hypoxia to stimulate endogenous production of erythropoietin to manage anemia.
Vafseo is now approved in 37 countries.
The approval of Vafseo ...